1. At a Glance
What happens when a 117-year-old pharma patriarch decides to reinvent itself as a real estate mogul? You get Alembic Ltd — the grand old man of Vadodara now busy selling penthouses instead of penicillin. The company, originally the proud parent of Alembic Pharma, has turned into a curious hybrid: part developer, part landlord, and part dividend-collecting uncle from Alembic Pharma Ltd (APL).
As of Q2 FY26, Alembic Ltd posted a net profit of ₹128 Cr on a modest revenue of ₹56 Cr. Sounds wild? That’s because 75 Cr+ of that came from “Other Income”, largely dividends and investment gains. Still, the company flaunts a 43.2% operating margin, a debt-to-equity ratio of 0.01, and a ROE of 13.7% — not bad for a business that now earns more from leasing offices and collecting dividends than manufacturing APIs.
At a market cap of ₹2,578 Cr and a P/E of just 7.98, the market seems to be treating this 100-rupee stock like old furniture, even though it quietly owns a 28.41% stake in Alembic Pharma (worth ₹6,800 Cr) and 19% in Paushak Ltd. Sometimes being old-school is the new cool.
2. Introduction – The Vadodara Veteran Who Won’t Retire
Imagine a company founded in 1907, surviving world wars, socialism, globalization, and now, meme stocks. That’s Alembic Ltd for you. Once India’s pharmaceutical pioneer, it spun off its main formulations arm into Alembic Pharmaceuticals Ltd (APL) in 2010 — and since then, has been living the “retired industrialist” life: real estate, dividends, and windmills.
But this retirement is profitable. Alembic’s Real Estate segment now forms 80% of revenue, compared to just 59% two years ago. Its residential projects — Samsara, Veda, Shangri La, and the iconic Alembic City — have transformed Vadodara’s skyline. And just when you thought it was done, it launches more high-rises: Veda-II, Kiara, and the upcoming Park Crescent.
Meanwhile, its API manufacturing business — the grand old chemical lab — has taken a backseat. Once a key revenue driver, it now contributes just 20% of total income, mostly on a job-work basis.
And in true Gujarati investor fashion, Alembic doesn’t like debt. With borrowings of just ₹14 Cr and Rs. 400 Cr invested in equity, the company seems to follow one motto — “When in doubt, collect dividends.”
3. Business Model – WTF Do They Even Do?
Good question. Because Alembic Ltd’s operations are like a Gujarati thali — a little bit of everything.
a) Real Estate (80% of FY24 revenue):
Alembic’s real estate arm builds premium residential and commercial projects. Think Vadodara’s Veda-II, a 22-story luxury apartment complex with 367 homes, and Kiara, a boutique 4BHK-only tower with 43 homes. They also run the Alembic Art District, a creative hub with galleries, studios, cafés, and even a skate park (because nothing says “legacy brand” like a half-pipe next to an art exhibit).
b) API Manufacturing (20% of FY24 revenue):
Still clinging to its pharma roots, Alembic makes APIs like Fluoxetine, Biphenyl Valine Oxalate, and Estolate. But this is now mostly a support act — fewer molecules, lower margins, and shrinking sales volumes.
c) Investments and Dividend Income:
Alembic Ltd is the proud parent and investor in Alembic Pharma (28.5% stake)
